Climb Bio Inc (CLYM) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Climb Bio Inc (CLYM) following the 2026 Q2 hedge fund 13F filings?

As of today, CLYM has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), CLYM gained +25.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Climb Bio Inc (CLYM)

78 + Investors. Track Smart Money conviction in CLYM. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CLYM

Based on 78 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds added CLYM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

78 hedge funds hold CLYM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +4% more funds vs a year ago

fund count last 6Q

+3 new funds entered over the past year (+4% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟢

More buyers than sellers — 60% buying

52 buying34 selling

Last quarter: 52 funds were net buyers (27 opened a brand new position + 25 added to an existing one). Only 34 were sellers (21 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+10 vs last Q)

new funds entering per quarter

Funds opening a new CLYM position: 18 → 11 → 17 → 27. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 38% entered in last year

■ 23% conviction (2yr+) ■ 38% medium ■ 38% new

Only 18 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💰

Value +40% but shares only +4% — price-driven

Value

+39%

+4%

Last quarter: the total dollar value of institutional holdings rose +40%, but actual share count only changed +4%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.

🚀

Acceleration phase — new buyers rushing in

15 → 18 → 11 → 17 → 27 new funds/Q

New funds entering each quarter: 18 → 11 → 17 → 27. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

📊

Mixed cohorts — 36% veterans, 38% new entrants

■ 36% veterans ■ 26% 1-2yr ■ 38% new

Of 80 current holders: 29 (36%) held 2+ years, 21 held 1–2 years, 30 (38%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

📋

Smaller funds dominant — 14% AUM from top-100

14% from top-100 AUM funds

24 of 78 holders rank in the top 100 by AUM, but together hold only 14% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

4.0

out of 10

Moderate Exit Risk

Exit risk score 4.0/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	78	64	21.88%
13F Shares	32M	31M	4.05%
Total Value	$209M	$150M	39.6%
New Positions	27	17	+10
Increased Positions	26	21	+5
Closed Positions	13	19	-6
Reduced Positions	20	20	-
Total Calls	2	0	100%
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

21.88%

13F Shares

32M

31M

4.05%

Total Value

$209M

$150M

39.6%

New Positions

+10

Increased Positions

Closed Positions

-6

Reduced Positions

Total Calls

100%

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

78 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CLYM. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CLYM holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Superstring Capital Management LP	4.29%	521,082	$6.8M
2	Ally Bridge Group (NY) LLC	2.87%	249,172	$3.2M
3	Great Point Partners LLC	2.46%	1,000,000	$13.0M
4	Stempoint Capital LP	1.67%	742,745	$9.7M
5	Cormorant Asset Management, LP	1.41%	2,106,000	$27.5M
6	Braidwell LP	1.35%	2,797,375	$36.5M
7	Ra Capital Management, L.P.	1.28%	11,300,939	$147.4M
8	Redmile Group, LLC	1.07%	1,226,330	$16.0M
9	Sphera Funds Management LTD.	0.82%	483,747	$6.3M
10	Parkman Healthcare Partners LLC	0.75%	563,484	$7.3M
11	Verdad Advisers, LP	0.58%	46,115	$601K
12	Affinity Asset Advisors, LLC	0.57%	972,000	$12.7M
13	ADAR1 Capital Management, LLC	0.49%	822,649	$10.7M
14	NAN FUNG TRINITY (HK) Ltd	0.46%	360,654	$4.7M
15	Ikarian Capital, LLC	0.42%	300,000	$3.9M
16	ArchPoint Investors	0.36%	128,900	$1.7M
17	Spark Investment Management LLC	0.35%	13,600	$177K
18	Frontier Capital Management Co LLC	0.24%	1,939,019	$25.3M
19	Virtus Investment Advisers, LLC	0.09%	28,602	$373K
20	Informed Momentum Co LLC	0.08%	69,657	$908K
21	Integrated Quantitative Investments LLC	0.07%	31,406	$410K
22	Woodline Partners LP	0.06%	1,582,291	$20.6M
23	Driehaus Capital Management LLC	0.06%	790,000	$10.3M
24	Cambria Investment Management, L.P.	0.05%	76,109	$992K
25	Adage Capital Partners GP, L.L.C.	0.05%	2,506,000	$32.7M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Climb Bio Inc (CLYM)

What does the Smart Money Trend signal show for CLYM?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added CLYM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CLYM?

More buyers than sellers — 60% buying: Last quarter: 52 funds were net buyers (27 opened a brand new position + 25 added to an existing one). Only 34 were sellers (21 trimmed + 13 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CLYM holders?

Smaller funds dominant — 14% AUM from top-100: 24 of 78 holders rank in the top 100 by AUM, but together hold only 14% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held CLYM?

Mostly new holders — 38% entered in last year: Only 18 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Climb Bio Inc (CLYM) following the 2026 Q2 hedge fund 13F filings?

As of today, CLYM has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), CLYM has gained +25.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Climb Bio Inc (CLYM)

Smart Money Signals — CLYM

Buying streak — 1 quarter in a row

At the ownership peak (100% of max)

Steady growth — +4% more funds vs a year ago

More buyers than sellers — 60% buying

More new buyers each quarter (+10 vs last Q)

Mostly new holders — 38% entered in last year

Value +40% but shares only +4% — price-driven

Acceleration phase — new buyers rushing in

Mixed cohorts — 36% veterans, 38% new entrants

Smaller funds dominant — 14% AUM from top-100

Institutional Sentiment Summary — CLYM

Hedge Fund Ownership: CLYM

Market Analysis: CLYM

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CLYM

Is It Too Late to Buy Climb Bio Inc (CLYM) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: CLYM

Statistics: CLYM

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Climb Bio Inc (CLYM)

Welcome to 13Foresight!